Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.34
+0.66000.45%
Pre-market: 146.340.00000.00%07:39 EDT
Volume:6.59M
Turnover:963.52M
Market Cap:181.56B
PE:-55.96
High:147.22
Open:144.23
Low:143.18
Close:145.68
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.32
T/O Rate:0.53%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.35
PE(LYR):21.58

Loading ...

RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 07

Citizens biotech analyst holds an analyst/industry conference call

TIPRANKS
·
Jul 07

Gilead Sciences Raised to Buy from Hold by HSBC

Dow Jones
·
Jul 06

U.S. Research Roundup-east West Bancorp, First Citizens Bancshares, UMB Financial

Reuters
·
Jul 06

Gilead : HSBC Raises to Buy from Hold; Raises Target Price to $155 from $133

THOMSON REUTERS
·
Jul 06

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 03

Moderna Inc. Stock Rises 10.0%, Outperforms Peers

Dow Jones
·
Jul 03

Gilead CEO Daniel O’day Disposes of 15,000 Common Shares Worth $1.89 Million

Reuters
·
Jul 03

Citizens biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 03

Trial for Bundibugyo Ebola Treatment Starts in DRC, WHO Says

Reuters
·
Jul 03

Gilead Donates over 2,000 Vials of Remdesivir to Support Who-led Ebola Treatment Trial

Reuters
·
Jul 03

Movement Alert|Gilead Sciences Rises 3.06% in Regular Trading, Trodelvy Wins FDA Approval for First-Line Triple-Negative Breast Cancer

Market Focus
·
Jul 02

Gilead Declares Q2 2026 Distribution of R$ 1.44 Per Unit, Payable July 3

Reuters
·
Jul 01

Africa CDC Seeks $18 Million in Urgent Support for Ebola Drug Trials in DRC

Reuters
·
Jun 30

Gilead Sciences Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jun 30

Moderna Inc. Stock Climbs 12.6%, Outperforms Peers

Dow Jones
·
Jun 27

Movement Alert|Gilead Sciences Rises 3.18% in Regular Trading, Trodelvy Wins FDA Approval for First-Line Triple-Negative Breast Cancer Treatment

Market Focus
·
Jun 26

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Jun 26

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy

TIPRANKS
·
Jun 25